Valeant Pharma (NYSE: VRX) is on watch following a new article from ProPublica which highlights documents that raise new questions ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE